Skip to main content
Delfa

← All assets

Bryostatin 1

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

0

Recruiting

0

Completed

3

Sites

61

Countries

1

Endpoints

61

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 61 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1/2
1
Phase 2
4

Trials by status

Completed
3
Terminated
1
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
33
Safety / tolerability / PK
13
Other (unclassified)
13
Function / daily living
1
Other clinical outcomes
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 10 of 61 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

8

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT02431468A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Bryostatin 1

Alzheimer’s disease

Alzheimer's diseasePh 2Completed29Feb 2017-results
NCT03560245A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

Bryostatin 1

Alzheimer’s disease

Alzheimer's diseasePh 2Completed28Jul 2019-results
NCT04538066Bryostatin Treatment of Moderately Severe Alzheimer's Disease

Bryostatin 1

Alzheimer’s disease

Alzheimer's diseasePh 2Completed19Nov 2022-results
NCT00606164Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

Bryostatin 1

Alzheimer’s disease

Alzheimer's diseasePh 2Unknown1Dec 2008-
NCT02221947Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

Bryostatin 1

Alzheimer’s disease

prodromal ADPh 1/2Terminated1Dec 2014-results

Showing 1-5 of 5 trials